For research purposes only — These compounds aren't FDA approved. All data presented is from clinical trials for educational reference.
Semax
Cognitive & Neuroprotective Peptide
Dosage
Quantity
Price
$26.99
Free shipping on orders $150+
60-day money-back guarantee
Secure checkout
Made in the USA
Certificate of Analysis
Batch verified lab data
99.93%
Purity
- Variant
- Semax 10mg
- Lot #
- A0112
- Labeled
- 20mg
- Actual
- 22.56mg
- Tested
- Feb 4, 2026
Frequently Researched Together
View allResearch Purposes Snapshot
Semax is a synthetic heptapeptide (ACTH4–7 analog extended with Pro-Gly-Pro) developed in Russia with decades of intranasal clinical use for neurologic indications. Summaries below are educational—this listing is not an FDA-approved drug claim in the United States.
~1.4×
BDNF increase
Hippocampal BDNF protein elevations reported after intranasal exposure in rodent pharmacology.
~3×
Gene expression
Exon III BDNF mRNA upregulation after single-dose protocols in published IMG work.
24h+
Duration cue
Pro-Gly-Pro tail extends plasma stability versus shorter ACTH fragments in PK discussions.
~1.6×
TrkB activation
Increased TrkB phosphorylation readouts alongside BDNF axis engagement in model systems.
7 aa
Heptapeptide
Sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP).
Development status
Regulatory information
Developed at the Institute of Molecular Genetics, Russian Academy of Sciences. Marketed as prescription nasal sprays in Russia for selected neurologic indications—not cleared by FDA for any use in the US.
- Developer
- Russian Academy of Sciences (IMG)
- Approval
- Russia (1990s onward)
- Indications (national labels)
- Stroke recovery, cognitive impairment (context-dependent)
- Formulations
- 0.1% and 1% intranasal spray
- US status
- Not FDA-approved
- Related peptide
- Selank (separate tuftsin-family analog)
What research has shown
Russian preclinical/clinical literature and review summaries
Molecular readouts (rodent models)
~3× BDNF mRNA after single dose
BDNF / TrkB axis (bars scaled to max ~300% for comparison)
Intranasal Semax (~50 mcg/kg in cited rat work) at IMG was associated with rapid neurotrophin expression changes and improved conditioned avoidance performance—species- and dose-specific.
Trace statistics to Russian primary pharmacology papers.
Research outcomes
Key findings from studies
Beyond cognitive enhancement
Multi-system motifs in reviews
BDNF
Neuroprotection
Plasticity and repair signaling in hippocampal circuits.
Stroke
Neuroprotection
Licensed clinical niche in Russia; motor recovery narratives.
VEGF
Vascular support
Angiogenesis-associated gene programs after CNS injury models.
No ACTH
Safety profile
ACTH analog without systemic corticotropic activity in standard doses.
Cognitive enhancement
Nootropic effects
Learning, memory, and attention improvements are attributed to BDNF–TrkB engagement in hippocampal summaries.
- Memory↑ enhanced
- Learning↑ improved
- Attention↑ sharpened
- Focus↑ sustained
Conditioned avoidance improvements are a recurring behavioral endpoint in rodent Semax papers.
Neuroprotection
Stroke recovery support
Russian clinical experience emphasizes motor and functional gains during early rehabilitation—figures below are illustrative review scales, not universal effect sizes.
Vascular health
Angiogenesis support
Gene-expression reviews cite VEGF-family upregulation and improved perfusion metrics after experimental brain injury.
- VEGF genes↑ upregulated
- Angiogenesis↑ promoted
- Blood flow↑ improved
- Neurovascular unit✓ supported
Stress response
Adaptive regulation
As an ACTH4–7-derived peptide, Semax is discussed in melanocortin / stress-adaptation frameworks without the adrenal steroid surge associated with full ACTH.
MC — melanocortin pathway modulation
Key advantage: retains cognitive and neurotrophic narratives linked to ACTH fragments while lacking systemic hormonal activity at therapeutic exposures in summarized data.
Safety profile from research
Russian clinical experience since the 1990s (summaries)
Reviews describe favorable tolerability with mostly mild, route-related complaints. Unlike ACTH, Semax does not meaningfully stimulate cortisol release or disrupt HPA homeostasis in cited dose ranges.
Frequently reported mild events
Nasal irritation
MildMild headache
MildDizziness
MildTaste disturbance
MildNo hormonal ACTH effects
Comparative safety text contrasts Semax with systemic ACTH on adrenal stimulation and steroid-related adverse profiles.
- No cortisol excursions in standard summarized doses
- No adrenal cortex stimulation narrative like injectable ACTH
- No HPA-axis suppression / rebound patterns attributed to Semax monotherapy
- No steroid-type adverse-effect bundle in registry reviews
Formulation experience
- 0.1% nasal solutionWell tolerated
- 1% nasal solutionGood tolerability
- Long-term exposureNo major red flags in reviews
- No dependence pattern described in Russian clinical summaries.
- No withdrawal syndrome on cessation in those narratives.
- Hydrolysis to natural amino acids often cited for metabolic safety.
Planning flags
- Approved in Russia since the 1990s for stroke and cognitive impairment per national labeling.
- 0.1% and 1% nasal sprays are Rx products where legally marketed—not equivalent to research-grade vials.
- Not FDA-approved; most Western jurisdictions treat non-registered material as unapproved for human therapy.
Storage handling reference
Peptide handling
Cold
Lyophilized: store per COA / SOP.
Reconstitution
Sterile technique if non-intranasal prep.
Light
Protect during aliquoting.
Documentation
Log batch, route, and concentration.
Researcher notes
- Decades of Russian post-market exposure informs tolerability, yet Western regulatory files remain thin.
- Absence of ACTH-like hormonal effects is a recurring differentiator in safety reviews.
- Most AEs are mild, local (nasal), and transient.
- Stroke-rehab populations dominate clinical narratives—do not generalize to healthy volunteer data.
Important Research Notice
Not for human consumption. This product and all products are sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from journals and official publications but should be fact checked. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations and you do not intend to use it for human consumption.